A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of chemo-naive patients with stages III and IV non-small cell lung cancer (NSCLC)GRIGORESCU, Alexandru; CIULEANU, Tudor; FIROIU, Elena et al.Lung cancer. 2007, Vol 57, Num 2, pp 168-174, issn 0169-5002, 7 p.Article

Erlotinib in previously treated non-small-cell lung cancerSHEPHERD, Frances A; PEREIRA, José Rodrigues; VAN KOOTEN, Maximiliano et al.The New England journal of medicine. 2005, Vol 353, Num 2, pp 123-132, issn 0028-4793, 10 p.Article

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trialHEISS, Markus M; MURAWA, Pawel; GANEA-MOTAN, Elena et al.International journal of cancer (Print). 2010, Vol 127, Num 9, pp 2209-2221, issn 0020-7136, 13 p.Article

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 studyCIULEANU, Tudor; BRODOWICZ, Thomas; CUCEVIC, Branka et al.Lancet (British edition). 2009, Vol 374, Num 9699, pp 1432-1440, issn 0140-6736, 9 p.Article

A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancerGRØNBERG, Bjørn H; CIULEANU, Tudor; SUNDSTRØM, Stein et al.Lung cancer. 2012, Vol 78, Num 1, pp 63-69, issn 0169-5002, 7 p.Article

Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patientsSPECENIER, Pol M; CIULEANU, Tudor; LATZ, Jane E et al.Cancer chemotherapy and pharmacology. 2009, Vol 64, Num 2, pp 233-241, issn 0344-5704, 9 p.Article

Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemiaAUERBACH, Michael; SILBERSTEIN, Peter T; WEBB, R. Timothy et al.American journal of hematology. 2010, Vol 85, Num 9, pp 655-663, issn 0361-8609, 9 p.Article

A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabineCIULEANU, Tudor E; PAVLOVSKY, Alexander V; BODOKY, Gyorgy et al.European journal of cancer (1990). 2009, Vol 45, Num 9, pp 1589-1596, issn 0959-8049, 8 p.Article

Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung CancerSOCINSKI, Mark A; SMIT, Egbert F; JASSEM, Jacek et al.Journal of clinical oncology. 2009, Vol 27, Num 28, pp 4787-4792, issn 0732-183X, 6 p.Article

Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer : A phase III trialBRODOWICZ, Thomas; KRZAKOWSKI, Maciej; JASSEM, Jacek et al.Lung cancer. 2006, Vol 52, Num 2, pp 155-163, issn 0169-5002, 9 p.Article

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancerHIRSCH, Fred R; VARELLA-GARCIA, Marileila; VON PAWEL, Joachim et al.Journal of clinical oncology. 2006, Vol 24, Num 31, pp 5034-5042, issn 0732-183X, 9 p.Article

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer : results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). CommentaryTHATCHER, Nick; CHANG, Alex; CARROLL, Kevin et al.Lancet (British edition). 2005, Vol 366, Num 9496, pp 1507-1508, issn 0140-6736, 13 p.Article

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancerO'BRIEN, Mary E. R; CIULEANU, Tudor-Eliade; TSEKOV, Hristo et al.Journal of clinical oncology. 2006, Vol 24, Num 34, pp 5441-5447, issn 0732-183X, 7 p.Article

Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy : Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled StudySMITH, Robert E; AAPRO, Matti S; LUDWIG, Heinz et al.Journal of clinical oncology. 2008, Vol 26, Num 7, pp 1040-1050, issn 0732-183X, 11 p.Article

Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non―Small-Cell Lung Cancer: A Randomized, Controlled Phase III TrialRAMLAU, Rodryg; GORBUNOVA, Vera; REY, Augustin et al.Journal of clinical oncology. 2012, Vol 30, Num 29, pp 3640-3647, issn 0732-183X, 8 p.Article

Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal CancerPEETERS, Marc; JAY PRICE, Timothy; STRICKLAND, Andrew H et al.Journal of clinical oncology. 2010, Vol 28, Num 31, pp 4706-4713, issn 0732-183X, 8 p.Article

International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non―Small-Cell Lung Cancer: MONET 1SCAGLIOTTI, Giorgio V; VYNNYCHENKO, Ihor; DEDIU, Mircea et al.Journal of clinical oncology. 2012, Vol 30, Num 23, pp 2829-2836, issn 0732-183X, 8 p.Article

Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non―Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 StudyGOSS, Glenwood D; ARNOLD, Andrew; ELLIS, Peter M et al.Journal of clinical oncology. 2010, Vol 28, Num 1, pp 49-55, issn 0732-183X, 7 p.Article

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialGARON, Edward B; CIULEANU, Tudor-Eliade; CZYZEWICZ, Grzegorz et al.Lancet (British edition). 2014, Vol 384, Num 9944, pp 665-673, issn 0140-6736, 9 p.Article